Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 53-60 , May 2009

Bisphosphonates—What the Dentist Needs to Know: Practical Considerations

  • John E. Fantasia, DDS

      Affiliations

    • Chief, Division of Oral and Maxillofacial Pathology, Department of Dental Medicine, North Shore-Long Island Jewish Health System, Long Island Jewish Medical Center, New Hyde Park, NY
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Fantasia: Division of Oral and Maxillofacial Pathology, Department of Dental Medicine, North Shore-Long Island Jewish Health System, Long Island Jewish Medical Center, 270-05 76th Avenue, New Hyde Park, NY 11040

References 

  1. Mehrotra B, Fantasia J, Nissel-Horowitz S, et al. Osteonecrosis of the maxilla: An unusual complication of prolonged bisphosphonate therapy: A case report. Proc Am Soc Clin Oncol. 2003;22:795
  2. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2004;62:527
  3. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res. 2007;86:1013
  4. Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res. 2007;86:1022
  5. Sarasquete ME, Garcia-Sanz R, Marin L, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: A genome-wide single nucleotide polymorphism analysis. Blood. 2008;112:2709
  6. Scheper MA, Baros A, Chaisuparat R, et al: Effect of zoledronic acid on oral fibroblasts and epithelial cells: A potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol Epub 2008 Nov 27
  7. Landesberg R, Cozin M, Cremers S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 2008;66:839
  8. Hellstein JW. Bisphosphonate induced osteochemonecrosis of the jaws: An ounce of prevention may be worth a pound of cure. Spec Care Dentistry. 2006;26:8
  9. Lerner UH. Bone remodeling in post-menopausal osteoporosis. J Dent Res. 2006;85:584
  10. Saag K, Lindsay R, Kreigman A, et al. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone. 2007;40:1238
  11. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol. 2000;18:1378
  12. Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002;42:1228
  13. Raje N, Woo SB, Hande K, et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008;14:2387
  14. Berenson JR, Yellin O, Boccia RV, et al. Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss. Clin Cancer Res. 2008;14:6289
  15. Santini D, Vincenzi B, Hannon RA, et al. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Oncol Reports. 2006;15:1351
  16. Gleeson H, Wiltshire E, Briody J, et al. Childhood chronic recurrent multifocal osteomyelitis: Pamidronate therapy decreases pain and improves vertebral shape. J Rheumatol. 2008;35:707
  17. Gibbons CLMH, Petra M, Smith R, et al. Bisphosphonate treatment of benign multifocal and unifocal osteolytic tumours of bone. Sarcoma. 2003;7:35
  18. Cartos VM, Zhu S, Zavras A. Bisphosphonate use and the risk of adverse jaw outcomes: A medical claims study of 714,217 people. J Am Dent Assoc. 2008;139:23
  19. Grbic JT, Landesberg R, Lin SQ, et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial. J Am Dent Assoc. 2008;139:32
  20. Carey JJ, Palomo L. Bisphosphonates and osteonecrosis of the jaw: Innocent association or significant risk?. Cleveland Clinic J Med. 2008;75:871
  21. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone. 2008;43:222
  22. Woo SB, Hellstein JW, Kalmar JR. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753
  23. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:433
  24. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369
  25. Polizzotto MN, Cousins V, Schwarer AP. Bisphosphonate-associated osteonecrosis of the auditory canal. Br J Haematol. 2006;132:114
  26. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397
  27. Sedghizadeh PP, Kumar SKS, Gorur A, et al. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg. 2008;66:767
  28. Christgau S, Cloos PAC. Current and future applications of bone turnover markers. Clin Lab. 2003;49:439
  29. Bolland MJ, Grey AB, Horne AM, et al. Effects of intravenous zoledronate on bone turnover and BMD persists for at least 24 months. J Bone Miner Res. 2008;23:1304
  30. Generali D, Dovio A, Tampellini M. Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. Br J Cancer. 2008;98:1753
  31. Lehrer S, Montazem A, Ramanathan L, et al. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:389
  32. Alexandersen P, Peris P, Guañabens N, et al. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. J Bone Miner Res. 2005;20:588
  33. Chan KC, Fantasia J. Oral bisphosphonates and jaw osteonecrosis: Preliminary results of a single institution, retrospective analysis. Joint Meeting of the International Association of Oral Pathologists and American Academy of Oral and Maxillofacial Pathology, San Francisco June 2008;AAOMP abstract 174
  34. Edwards BJ, Hellstein JW, Jacobsen PL, et al. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: An advisor statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2008;139:1674
  35. Sedghizadeh PP, Stanley BS, Caligiuri M, et al. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw. J Am Dent Assoc. 2009;140:61
  36. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century?. J Oral Maxillofac Surg. 2005;63:682
  37. Donaghue AM. Bisphosphonates and osteonecrosis: Analogy to phossy jaw. Med J Aust. 2005;183:163
  38. Marx RE. Uncovering the cause of “phossy jaw” circa 1858 to 1906: Oral and maxillofacial surgery closed case file—Case closed. J Oral Maxillofac Surg. 2008;66:2356

 The author states no financial arrangement or affiliation with a corporate organization or a manufacturer of a product discussed in this article.

PII: S0278-2391(09)00118-9

doi: 10.1016/j.joms.2009.01.011

Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 53-60 , May 2009

Article Tools